|
|
||||||||
Departments of Nuclear Medicine and Diagnostic Radiology, University Hospital, Ulm, Germany
Correspondence: For correspondence or reprints contact: Sven N. Reske, MD, Department of Nuclear Medicine, University of Ulm, Robert Koch Str. 8, D-89070 Ulm, Germany.
ABSTRACT
Radionuclide bone scanning (RNB) is considered to be the most practical screening technique for assessing the entire skeleton for skeletal metastases. However, RNB has been shown to be of lower sensitivity than MRI and CT in detecting osteolytic metastases. A prospective study was designed to evaluate the accuracy of planar RNB versus tomographic bone imaging with 18F-labeled NaF and PET (18F PET) in detecting osteolytic and osteoblastic metastases and its dependency on their anatomic localization. Methods: Forty-four patients with known prostate, lung or thyroid carcinoma were examined with both planar RNB and 18F PET. A panel of reference methods including MRI of the spine, 131I scintigraphy, conventional radiography and spiral CT was used as the gold standard. RNB and 18F PET were compared by a lesion-by-lesion analysis using a five-point score for receiver operating characteristic (ROC) curve analysis. Results:: 18F PET showed 96 metastases (67 of prostate carcinoma and 29 of lung or thyroid cancer), whereas RNB revealed 46 metastases (33 of prostate carcinoma and 13 of lung or thyroid cancer). All lesions found with RNB were also detected with 18F PET. Compared with 18F PET and the reference methods, RNB had a sensitivity of 82.8% in detecting malignant and benign osseous lesions in the skull, thorax and extremities and a sensitivity of 40% in the spine and pelvis. The area under the ROC curve was 0.99 for 18F PET and 0.64 for RNB. Conclusion:: 18F PET is more sensitive than RNB in detecting osseous lesions. With RNB, sensitivity in detecting osseous metastases is highly dependent on anatomic localization of these lesions, whereas detection rates of osteoblastic and osteolytic metastases are similar. Higher detection rates and more accurate differentiation between benign and malignant lesions with 18F PET suggest the use of 18F PET when possible.
Key Words: 18F PET radionuclide bone scanning bone metastases
This article has been cited by other articles:
![]() |
F. D. Grant, F. H. Fahey, A. B. Packard, R. T. Davis, A. Alavi, and S. T. Treves Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer J. Nucl. Med., January 1, 2008; 49(1): 68 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. E. Lecouvet, D. Geukens, A. Stainier, F. Jamar, J. Jamart, B. J. d'Othee, P. Therasse, B. V. Berg, and B. Tombal Magnetic Resonance Imaging of the Axial Skeleton for Detecting Bone Metastases in Patients With High-Risk Prostate Cancer: Diagnostic and Cost-Effectiveness and Comparison With Current Detection Strategies J. Clin. Oncol., August 1, 2007; 25(22): 3281 - 3287. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Bridges, C. R. Wiley, J. C. Christian, and A. P. Strohm An Introduction to Na18F Bone Scintigraphy: Basic Principles, Advanced Imaging Concepts, and Case Examples J. Nucl. Med. Technol., June 1, 2007; 35(2): 64 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Taira, R. J. Herfkens, S. S. Gambhir, and A. Quon Detection of Bone Metastases: Assessment of Integrated FDG PET/CT Imaging Radiology, April 1, 2007; 243(1): 204 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Wade, J. A. Scott, I. Kuter, and A. J. Fischman Flare response in 18F-fluoride ion PET bone scanning. Am. J. Roentgenol., June 1, 2006; 186(6): 1783 - 1786. [Full Text] [PDF] |
||||
![]() |
F.-Y. Liu, J. T. Chang, H.-M. Wang, C.-T. Liao, C.-J. Kang, S.-K. Ng, S.-C. Chan, and T.-C. Yen [18F]Fluorodeoxyglucose Positron Emission Tomography Is More Sensitive Than Skeletal Scintigraphy for Detecting Bone Metastasis in Endemic Nasopharyngeal Carcinoma at Initial Staging J. Clin. Oncol., February 1, 2006; 24(4): 599 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Even-Sapir, U. Metser, E. Mishani, G. Lievshitz, H. Lerman, and I. Leibovitch The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT J. Nucl. Med., February 1, 2006; 47(2): 287 - 297. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Even-Sapir Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities J. Nucl. Med., August 1, 2005; 46(8): 1356 - 1367. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mazumdar Group Sequential Design for Comparative Diagnostic Accuracy Studies: Implications and Guidelines for Practitioners Med Decis Making, October 1, 2004; 24(5): 525 - 533. [Abstract] [PDF] |
||||
![]() |
T. Hamaoka, J. E. Madewell, D. A. Podoloff, G. N. Hortobagyi, and N. T. Ueno Bone Imaging in Metastatic Breast Cancer J. Clin. Oncol., July 15, 2004; 22(14): 2942 - 2953. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Even-Sapir, U. Metser, G. Flusser, L. Zuriel, Y. Kollender, H. Lerman, G. Lievshitz, I. Ron, and E. Mishani Assessment of Malignant Skeletal Disease: Initial Experience with 18F-Fluoride PET/CT and Comparison Between 18F-Fluoride PET and 18F-Fluoride PET/CT J. Nucl. Med., February 1, 2004; 45(2): 272 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Metser, H. Lerman, A. Blank, G. Lievshitz, F. Bokstein, and E. Even-Sapir Malignant Involvement of the Spine: Assessment by 18F-FDG PET/CT J. Nucl. Med., February 1, 2004; 45(2): 279 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Port, M. S. Kent, R. J. Korst, R. Keresztes, M. A. Levin, and N. K. Altorki Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer Ann. Thorac. Surg., January 1, 2004; 77(1): 254 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Khan, N Oriuchi, T Higuchi, H Zhang, and K Endo PET in the follow-up of differentiated thyroid cancer Br. J. Radiol., October 1, 2003; 76(910): 690 - 695. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Brenner, K. H. Bohuslavizki, and J. F. Eary PET Imaging of Osteosarcoma J. Nucl. Med., June 1, 2003; 44(6): 930 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.F. Vansteenkiste Imaging in lung cancer: positron emission tomography scan Eur. Respir. J., February 1, 2002; 19(35_suppl): 49S - 60s. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nunez, H. A. Macapinlac, H. W.D. Yeung, T. Akhurst, S. Cai, I. Osman, M. Gonen, E. Riedel, H. I. Scher, and S. M. Larson Combined 18F-FDG and 11C-Methionine PET Scans in Patients with Newly Progressive Metastatic Prostate Cancer J. Nucl. Med., January 1, 2002; 43(1): 46 - 55. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schirrmeister, G. Glatting, J. Hetzel, K. Nussle, C. Arslandemir, A. K. Buck, K. Dziuk, A. Gabelmann, S. N. Reske, and M. Hetzel Prospective Evaluation of the Clinical Value of Planar Bone Scans, SPECT, and 18F-Labeled NaF PET in Newly Diagnosed Lung Cancer J. Nucl. Med., December 1, 2001; 42(12): 1800 - 1804. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Piert, T. T. Zittel, G. A. Becker, M. Jahn, A. Stahlschmidt, G. Maier, H.-J. Machulla, and R. Bares Assessment of Porcine Bone Metabolism by Dynamic [18F]Fluoride Ion PET: Correlation with Bone Histomorphometry J. Nucl. Med., July 1, 2001; 42(7): 1091 - 1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.F. Vansteenkiste and S.G. Stroobants The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology Eur. Respir. J., April 1, 2001; 17(4): 802 - 820. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Messa, C. Landoni, C. Pozzato, and F. Fazio Is There a Role for FDG PET in the Diagnosis of Musculoskeletal Neoplasms? J. Nucl. Med., October 1, 2000; 41(10): 1702 - 1702. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |